GlassScriptPhysician profile
Supriya Ramesha
NPI 1487280442
$1,570.00
in general payments reported to CMS, 2019-2025
21 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $673 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.00 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $357.16 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $256.87 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $179.30 | 2024-2025 | Ingrezza |
| Abbvie INC. | $111.09 | 2024-2025 | |
| Biogen, INC. | $109.18 | 2024-2025 | Vumerity, Tysabri, Leqembi |
| Neurelis, INC. | $74.43 | 2024-2025 | Valtoco |
| Emd Serono, INC. | $62.78 | 2024-2025 | |
| Pfizer INC. | $60.29 | 2025 | |
| Acadia Pharmaceuticals INC | $52.79 | 2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $50.72 | 2024 | Ultomiris |
| Janssen Biotech, INC. | $33.48 | 2025 | |
| Kyowa Kirin, INC. | $26.09 | 2025 | |
| Merz Pharmaceuticals, LLC | $25.66 | 2025 | Xeomin |
| Tandem Diabetes Care, INC. | $25.50 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $23.32 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $22.06 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.39 | 2024 | Hyqvia |
| Argenx US, INC. | $21.15 | 2024 | Vyvgart Hytrulo |
| Corcept Therapeutics | $20.71 | 2025 | Korlym |
| Jazz Pharmaceuticals INC. | $18.58 | 2024 | |
| Lilly USA, LLC | $17.45 | 2024 | Emgality |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Ramesha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.